Equillium (EQ) Registration Filing summary

Company overview and business model

• Focuses on developing novel therapies for severe autoimmune and inflammatory disorders, with lead candidate EQ504 targeting the aryl hydrocarbon receptor pathway.

• Operates as a biotechnology innovator with three wholly-owned subsidiaries in the US and Australia.

• Incorporated in Delaware in 2017, with headquarters in La Jolla, California.

Financial performance and metrics

• Raised approximately $30 million in a private placement on August 12, 2025, selling shares and pre-funded warrants.

• Subject to certain conditions, may raise an additional $20 million in a subsequent closing.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; only nominal proceeds from warrant exercises.

• Bears registration and related expenses, while selling stockholders cover commissions and transfer taxes.